GSK: positive data for endometrial cancer

(CercleFinance.com) - Positive Phase III data from RUBY show the potential for Jemperli (dostarlimab) to be combined in a greater number of patients with advanced or recurrent primary endometrial cancer.


The combination of dostarlimab and chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival (OS) in the overall population.

The group reports a 31% reduction in the risk of death and a 16.4-month improvement in median OS observed with dostarlimab combined with chemotherapy versus chemotherapy in the overall population.

It also announced a 37% reduction in the risk of disease progression or death and a 6-month improvement in median progression-free survival observed with the addition of Zejula (niraparib) to maintenance dostarlimab after dostarlimab-associated chemotherapy versus chemotherapy in the MMR/MSS population where treatment options are still needed.

GSK said that the positive data presented today once again demonstrates how dostarlimab-based regimens could benefit a greater number of endometrial cancer patients. It aims to continue to find ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options.


Copyright (c) 2024 CercleFinance.com. All rights reserved.